Gene · 23533
Papers819
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 819
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Serglycin-ROS axis mediates synergistic lethality of PI3Kγ inhibition and Azacitidine in TP53-mutated AML. | BMC Cancer | 2026 | 42464230 | PubTator, text mining | PubMed |
| Systemic Drug Effects in Vortioxetine-Induced Time-Series Datasets. | Int J Mol Sci | 2026 | 42450323 | PubTator, text mining | PubMed |
| Screening of Inflammatory Biomarkers in Atherosclerosis Based on WGCNA Analysis and Machine Learning. | Curr Mol Med | 2026 | 42227555 | PubTator, text mining | PubMed |
| Mapping functional non-coding variation in individual human genomes through haplotyping, multiomics, and deep learning. | Nat Commun | 2026 | 42056104 | PubTator, text mining | PubMed |
| Leveraging Deep Learning to Construct a Programmed Cell Death-Driven Prognostic Signature in Acute Myeloid Leukemia. | Curr Issues Mol Biol | 2026 | 42042014 | PubTator, text mining | PubMed |
| ALOX5 Expression and Pathomics Features Reveal New Insights Into Lung Adenocarcinoma Prognosis: Model Construction and Functional Validation. | Hum Mutat | 2026 | 41809565 | PubTator, text mining | PubMed |
| New Dual Pan-PI3K/mTOR Inhibitor: Design, Synthesis, Cytotoxic Action, Permeation, Metabolic Stability, and In Silico Protein-Ligand Interaction. | ACS Omega | 2026 | 41726721 | PubTator, text mining | PubMed |
| NF-κB and STAT3 signaling uniquely stratify survival in female glioblastoma patients. | iScience | 2026 | 41716996 | PubTator, text mining | PubMed |
| Effects of ascorbic acid on trabecular meshwork gene expression and collagen secretion. | BMJ Open Ophthalmol | 2026 | 41692493 | PubTator, text mining | PubMed |
| The impact of PANoptosis-related genes on immune profiles and subtype classification in ischemic stroke. | Sci Rep | 2025 | 41136446 | PubTator, text mining | PubMed |
| The double-edged sword of PI3Kδ pathway-related immune dysregulation: insights from two case reports. | Immunol Res | 2025 | 40971032 | PubTator, text mining | PubMed |
| Recognition of molecular clusters and a novel prognostic signature based on natural killer cell-related genes in skin cutaneous melanoma. | World J Surg Oncol | 2025 | 40903770 | PubTator, text mining | PubMed |
| Development of a Mitochondrial Permeability Transition-Driven Necrosis-Related Prognostic Signature in Cervical Cancer: Integrating Bulk Transcriptomic and Single-Cell Data. | Cancer Med | 2025 | 40747615 | PubTator, text mining | PubMed |
| PI3K/AKT/mTOR Axis in Cancer: From Pathogenesis to Treatment. | MedComm (2020) | 2025 | 40740483 | PubTator, text mining | PubMed |
| Collagen XVII Promotes Pancreatic Ductal Adenocarcinoma Tumor Growth through Regulation of PIK3R5. | Cancer Res Commun | 2025 | 40728119 | PubTator, text mining | PubMed |
| PI3K/AKT signaling pathway plays an important role in the pathogenesis of metabolic dysfunction-associated steatotic liver disease. | Sci Rep | 2025 | 40594616 | PubTator, text mining | PubMed |
| Cytohesin-4/ARF6 facilitates the progression of acute myeloid leukemia through activating PIK3R5/PI3K/AKT pathway. | iScience | 2025 | 40502711 | PubTator, text mining | PubMed |
| GWAS of multiple neuropathology endophenotypes identifies new risk loci and provides insights into the genetic risk of dementia. | Nat Genet | 2024 | 39379761 | PubTator, text mining | PubMed |
| Generation of novel lipid metabolism-based signatures to predict prognosis and immunotherapy response for colorectal adenocarcinoma. | Sci Rep | 2024 | 39060344 | PubTator, text mining | PubMed |
| Targeting a lineage-specific PI3Kɣ-Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule. | Nat Cancer | 2024 | 38816660 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/23533/papers